Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion

International Journal of Cancer

Volumn 133, Issue 3, 2013, Pages 645-652

  Han, Hye Suk ^a   Yun, Jieun ^b   Lim, Sung Nam ^a   Han, Joung Ho ^a   Lee, Ki Hyeong ^a   Kim, Seung Taik ^a   Kang, Min Ho ^a   Son, Seung Myoung ^a   Lee, Yong Moon ^a   Choi, Song Yi ^a   Yun, Seok Joong ^a   Kim, Wun Jae ^a   Lee, Ok Jun ^a  

^a Chungbuk National University College of Medicine   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

CEA; CYFRA 21 1; lung adenocarcinoma; miR 198; pleural effusion

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; MICRORNA; MICRORNA 198; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PLEURA EFFUSION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; DIAGNOSIS, DIFFERENTIAL; DOWN-REGULATION; FEMALE; HUMANS; KERATIN-19; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLEURAL EFFUSION, MALIGNANT; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84877999130     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28054     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Antony VB, Loddenkemper R, Astoul P, et al. Management of malignant pleural effusions. Eur Respir J 2001; 18: 402-19.
3. Tsim S, O'Dowd CA, Milroy R, et al. Staging of non-small cell lung cancer (NSCLC): a review. Respir Med 2010; 104: 1767-74.
4. Nance KV, Shermer RW, Askin FB,. Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination. Mod Pathol 1991; 4: 320-4.
5. Ong KC, Indumathi V, Poh WT, et al. The diagnostic yield of pleural fluid cytology in malignant pleural effusions. Singapore Med J 2000; 41: 19-23.
6. Maskell NA, Gleeson FV, Davies RJ,. Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial. Lancet 2003; 361: 1326-30.
7. Rodriguez-Panadero F, Janssen JP, Astoul P,. Thoracoscopy: general overview and place in the diagnosis and management of pleural effusion. Eur Respir J 2006; 28: 409-22.
8. Huang WW, Tsao SM, Lai CL, et al. Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma. Pathology 2010; 42: 224-8.
9. Gu P, Huang G, Chen Y, et al. Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21-1 in patients with pleural effusion: a systematic review and meta-analysis. J Clin Lab Anal 2007; 21: 398-405.
10. Shitrit D, Zingerman B, Shitrit AB, et al. Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist 2005; 10: 501-7.
11. Ambros V,. The functions of animal microRNAs. Nature 2004; 431: 350-5.
12. Bartel DP,. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
13. Melo SA, Esteller M,. Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett 2011; 585: 2087-99.
14. Heneghan HM, Miller N, Kerin MJ,. MiRNAs as biomarkers and therapeutic targets in cancer. Curr Opin Pharmacol 2010; 10: 543-50.
15. Cho WC,. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 2010; 42: 1273-81.
16. Cho WC,. As in cancer-from research to therapy. Biochim Biophys Acta 2010; 1805: 209-17.
17. Cherni I, Weiss GJ,. miRNAs in lung cancer: large roles for small players. Future Oncol 2011; 7: 1045-55.
18. Skrzypski M, Dziadziuszko R, Jassem J,. MicroRNA in lung cancer diagnostics and treatment. Mutat Res 2011; 717: 25-31.
19. Markou A, Liang Y, Lianidou E,. Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer. Clin Chem Lab Med 2011; 49: 1591-603.
20. Gee GV, Koestler DC, Christensen BC, et al. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. Int J Cancer 2010; 127: 2859-69.
21. Roth C, Stückrath I, Pantel K, et al. Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors. PLoS One 2012; 7: e38248.
22. Fleischhacker M, Schmidt B,. Free circulating nucleic acids in plasma and serum (CNAPS) - Useful for the detection of lung cancer patients? Cancer Biomark 2010; 6: 211-9.
23. Zhou L, Zhao YP, Liu WJ, et al. Circulating microRNAs in cancer: diagnostic and prognostic significance. Expert Rev Anticancer Ther 2012; 12: 283-8.
24. Cho WC,. Circulating MicroRNAs as Minimally Invasive Biomarkers for Cancer Theragnosis and Prognosis. Front Genet 2011; 2: 7.
25. Cortez MA, Bueso-Ramos C, Ferdin J, et al. MicroRNAs in body fluids - the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011; 8: 467-77.
26. Etheridge A, Lee I, Hood L, et al. Extracellular microRNA: a new source of biomarkers. Mutat Res 2011; 717: 85-90.
27. Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56: 1733-41.
28. Xie L, Chen X, Wang L, et al. Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions. BMC Cancer 2010; 10: 591.
29. Xie L, Wang T, Yu S, et al. Cell-free miR-24 and miR-30d, potential diagnostic biomarkers in malignant effusions. Clin Biochem 2011; 44: 216-20.
30. Mestdagh P, Van Vlierberghe P, De Weer A, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 2009; 10: R64.
31. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009; 55: 611-22.
32. Ratert N, Meyer HA, Jung M, et al. Reference miRNAs for miRNAome analysis of urothelial carcinomas. PLoS One 2012; 7: e39309.
33. Davoren PA, McNeill RE, Lowery AJ, et al. Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol 2008; 9: 76.
34. Gee HE, Buffa FM, Camps C, et al. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer 2011; 104: 1168-77.
35. Song J, Bai Z, Han W, et al. Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci 2012; 57: 897-904.
36. Varnholt H, Drebber U, Schulze F, et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008; 47: 1223-32.
37. Tan S, Li R, Ding K, et al. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett 2011; 585: 2229-34.
38. Ma PC, Tretiakova MS, MacKinnon AC, et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 2008; 47: 1025-37.
39. Ma PC, Maulik G, Christensen J, et al. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003; 22: 309-25.
40. Feng Y, Thiagarajan PS, Ma PC,. MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol 2012; 7: 459-67.
41. Tachibana K, Minami Y, Shiba-Ishii A, et al. Abnormality of the hepatocyte growth factor/MET pathway in pulmonary adenocarcinogenesis. Lung Cancer 2012; 75: 181-8.
42. Tanaka A, Sueoka-Aragane N, Nakamura T, et al. Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients. Lung Cancer 2012; 75: 89-94.
43. Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008; 68: 9479-87.
44. Gambari R,. Peptide-nucleic acids (PNAs): a tool for the development of gene expression modifiers. Curr Pharm Des 2001; 7: 1839-62.
45. Lundin KE, Good L, Strömberg R, et al. Biological activity and biotechnological aspects of peptide nucleic acid. Adv Genet 2006; 56: 1-51.